CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse.

• DOI: 10.22038/ijbms.2017.8231
• Publication Date: 2017-02-01
• Authors: Ali Asghar Baghani; Saman Soleimanpour; Hadi Farsiani; Arman Mosavat; Masoud Yousefi; Zahra Meshkat; Seyed Abdolrahim ...; Saeid Amel Jamehdar; M R Akbari Eydgahi; Hamid Sadeghian; Kiarash Ghazvini
• Keywords: 0303 health sciences; 03 medical and health sciences; CFP-10; R; Medicine; Original Article; Mycobacterium tuberculosis; Immunogenicity; Subunit vaccine; 3. Good health; Fcγ2a

Despite treatment with antibiotics and vaccination BCG, tuberculosis (TB) is still considered as one of the most important public health problems in world. Therefore, designing producing a more effective vaccine against TB seems urgently. In this study, immunogenicity fusion protein which consisting or comprising CFP-10 from Mycobacterium Fc-domain mouse IgG2a was evaluated novel subunit candidate TB.The genetic constructs were cloned pPICZαA expression vector recombinant vectors (pPICZαA-CFP-10: Fcγ2a pPICZαA-CFP-10:His) transformed into Pichia pastoris. To evaluate proteins, SDS-PAGE immunoblotting used. The without BCG assessed BALB/c mice specific cytokines proteins (IFN-γ, IL-12, IL-4, IL-17 TGF-β) evaluated.The levels IFN-γ IL-12 that received higher than control groups (BCG PBS). Thus, both (CFP-10:Fcγ2a CFP-10:His) could excite good response Th1-cells. Fc-tagged had stronger Th1 low compared to CFP-10:His. However, highest level observed vaccinated (prime) then CFP-10: (booster).The results demonstrated binding can increase vaccine. Further studies, might be able design produce new generation vaccines based on Fc-fused immunogen.